Unmet Need after Lung Transplant
~50% mortality in the first 5 years post-transplant
- 2-3 times higher mortality rate compared to kidney and liver transplant
Leading cause of death is Chronic lung allograft dysfunction (CLAD)
- 3-5 years median survival after the diagnosis of CLAD
- ~10% of patients develop CLAD every year
Acute cellular rejection (ACR) is a significant risk factor for CLAD
- ~30% of patients develop ACR in the first year post-transplant
- Risk of CLAD increases with number and severity of rejections
High toxicity associated with oral tacrolimus, the standard of care therapy in > 90% of patients
- ~67% of patients develop >= Stage 3 Chronic Kidney Disease 1 year post-transplant
- ~33% of patients develop diabetes 5 years post-transplant
- ~30% of patients develop malignancies 10 years post-transplant
- ~25% of patients develop severe kidney dysfunction, creatinine > 2.5 mg/dL, needing chronic dialysis or kidney transplant 10 years post-transplant
Our Mission
Improving lives after lung transplant
Our Focus
Canvas is focusing on Tacrolimus Inhalation Powder as a targeted solution to ACR, CLAD and high tacrolimus toxicities.
Tacrolimus Inhalation Powder, is a novel, patented dry powder formulation of tacrolimus for direct-to-lung delivery with unique pharmacokinetic properties to improve tacrolimus efficacy and reduce toxicities.
